Skip to main content

Advertisement

SpringerLink
Log in

Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma

  • Lymphomas (MR Smith, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Availability of highly effective novel agents has altered the approach to initial therapy in patients with classical Hodgkin lymphoma (cHL). We will review controversies in the following areas: (1) the role of radiation in early unfavorable disease and the optimal treatment strategies for (2) advanced-stage disease and (3) elderly patients.

Recent Findings

Strategies incorporating brentuximab vedotin into frontline treatment of cHL yielded favorable results in non-randomized elderly studies and were compared to ABVD in advanced disease among adults. Meanwhile, four cycles of escalated BEACOPP yielded unprecedented favorable results for the treatment of advanced disease in the German Hodgkin Study Group 18 study.

Summary

The addition of novel agents to conventional treatment strategies has the potential to improve outcomes in high-risk groups of patients while reducing toxicity. The role of radiation therapy remains in question but may see diminished use with the incorporation of more effective agents in the frontline setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–607 Established the role of 3 cycles of AVD without radiation for early-stage Hodgkin lymphoma.

    Article  CAS  Google Scholar 

  2. Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199–206.

    Article  Google Scholar 

  3. Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007;25(23):3495–502.

    Article  CAS  Google Scholar 

  4. Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2003;21(19):3601–8.

    Article  Google Scholar 

  5. Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–52.

    Article  CAS  Google Scholar 

  6. Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev. 2017;5:CD007941.

    PubMed  Google Scholar 

  7. •• Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374(25):2419–29 The largest trial of PET-de-escalation in advanced Hodgkin lymphoma. Established the safety of bleomycin omission following 2 cycles of ABVD in patients with an interim complete metabolic response.

    Article  Google Scholar 

  8. Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015;373(26):2499–511.

    Article  CAS  Google Scholar 

  9. Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, et al. Treatment of stage I-II A non-bulky Hodgkin’s lymphoma (HL): an individual patient-data comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 combined-modality therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone. Blood. 2015;120(21):548.

    Google Scholar 

  10. Ng AK, LaCasce A, Travis LB. Long-term complications of lymphoma and its treatment. J Clin Oncol. 2011;29(14):1885–92.

    Article  Google Scholar 

  11. Kobe C, Dietlein M, Kriz J, Furth C, Fuchs M, Borchmann P, et al. The role of PET in Hodgkin’s lymphoma and its impact on radiation oncology. Expert Rev Anticancer Ther. 2010;10(9):1419–28.

    Article  Google Scholar 

  12. Goodman KA, Riedel E, Serrano V, Gulati S, Moskowitz CH, Yahalom J. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin’s lymphoma. J Clin Oncol. 2008;26(32):5240–7.

    Article  Google Scholar 

  13. Brusamolino E, Baio A, Orlandi E, Arcaini L, Passamonti F, Griva V, et al. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin’s lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res. 2006;12(21):6487–93.

    Article  CAS  Google Scholar 

  14. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol. 2004;22(14):2835–41.

    Article  Google Scholar 

  15. Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–62.

    Article  Google Scholar 

  16. Dhakal S, Advani R, Ballas LK, Dabaja BS, Flowers CR, Ha CS, et al. ACR Appropriateness Criteria(R) Hodgkin lymphoma-favorable prognosis stage I and II. Am J Clin Oncol. 2016;39(6):535–44.

    Article  CAS  Google Scholar 

  17. Roberts KB, Younes A, Hodgson DC, Advani R, Dabaja BS, Dhakal S, et al. ACR Appropriateness Criteria(R) Hodgkin lymphoma-unfavorable clinical stage I and II. Am J Clin Oncol. 2016;39(4):384–95.

    Article  Google Scholar 

  18. Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Munck af Rosenschold P, Petersen PM, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol. 2013;24(8):2113–8.

    Article  CAS  Google Scholar 

  19. Raemaekers JM, Andre MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32(12):1188–94.

    Article  Google Scholar 

  20. •• Andre MP, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017:Jco2016686394. One of the largest trials of PET-adapted therapy in early-stage patients. Demonstrated potential safety of omission of radiation therapy in some patients with early unfavorable disease and a complete metabolic remission.

  21. Savage KJ, Connors JM, Klasa RJ, Hoskins P, Shenkier TN, Gascoyne RD, et al. The use of FDG-PET to guide consolidative radiotherapy in patients with advanced-stage Hodgkin lymphoma with residual abnormalities on CT scan following ABVD chemotherapy. J Clin Oncol. 2011;29(15_suppl):8034.

    Article  Google Scholar 

  22. Savage KJ, Connors JM, Villa DR, Hapgood G, Gerrie AS, Shenkier TN, et al. Advanced stage classical Hodgkin lymphoma patients with a negative PET-scan following treatment with ABVD have excellent outcomes without the need for consolidative radiotherapy regardless of disease bulk at presentation. Blood. 2015;126(23):579.

    Google Scholar 

  23. • Press OW, Li H, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M, et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016. One of the first trials of PET-adapted therapy in advanced-stage Hodgkin lymphoma.

  24. •• Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mule A, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol. 2018;36(5):454–62 One of the largest trials of PET-adapted therapy in early-stage patients. Further established safety of escalated BEACOPP in patients failing to achieve complete metabolic remission after 2 cycles of ABVD.

    Article  CAS  Google Scholar 

  25. Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, et al. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood. 2018;132(10):1013–21.

    Article  CAS  Google Scholar 

  26. •• Friedberg JW, Forero-Torres A, Bordoni RE, Cline VJM, Patel Donnelly D, Flynn PJ, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged >/=60 years with HL. Blood. 2017;130(26):2829–37 The first clinical trial incorporating novel therapy and omitting anthracycline in newly diagnosed elderly Hodgkin patients. Results showed improved safety and efficacy compared to historic cohorts.

    Article  CAS  Google Scholar 

  27. •• Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol. 2018:JCO2018790139. One of the first trials incorporating novel therapy into newly diagnosed elderly Hodgkin lymphoma. Results showed improved safety and efficacy compared to historic cohorts.

  28. Klimm B, Goergen H, Fuchs M, von Tresckow B, Böll B, Meissner J, et al. Impact of risk factors on outcomes in early-stage Hodgkin’s lymphoma: an analysis of international staging definitions. Ann Oncol. 2013;24(12):3070–6.

    Article  CAS  Google Scholar 

  29. Gunther JR, Fanale MA, Reddy JP, Akhtari M, Smith GL, Pinnix CC, et al. Treatment of early-stage unfavorable Hodgkin lymphoma: efficacy and toxicity of 4 versus 6 cycles of ABVD chemotherapy with radiation. Int J Radiat Oncol Biol Phys. 2016;96(1):110–8.

    Article  Google Scholar 

  30. von Tresckow B, Plutschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30(9):907–13.

    Article  Google Scholar 

  31. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366(5):399–408.

    Article  CAS  Google Scholar 

  32. Fiaccadori V et al. Relapses in early PET-negative stage I/II Hodgkin lymphoma after combined modality treatment or chemotherapy only in the EORTC/LYSA/FIL H10 trial. Abstract # 0066. International Symposium of Hodgkin Lymphoma; Cologne, Germany 2018.

  33. Nguyen VT, Pophali PA, Tsai JP, Jagadeesh D, Dean RM, Pohlman B, et al. Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of PET scan in treatment planning. Br J Haematol. 2017;179(4):674–6.

    Article  Google Scholar 

  34. Master S, Koshy N, Wilkinson B, Rosen L, Mills G, Mansour R, et al. Effect of radiation therapy on survival in Hodgkin’s lymphoma: a SEER data analysis. Anticancer Res. 2017;37(6):3035–43.

    CAS  PubMed  Google Scholar 

  35. Younes A, Connors JM, Park SI, Fanale M, O’Meara MM, Hunder NN, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–56.

    Article  CAS  Google Scholar 

  36. Kumar A, Casulo C, Yahalom J, Schoder H, Barr PM, Caron P, et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016;128(11):1458–64.

    Article  CAS  Google Scholar 

  37. Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, et al. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score >/= 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 intergroup trial. J Clin Oncol. 2016;34:2028–36.

    Article  CAS  Google Scholar 

  38. Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013;31(6):684–91.

    Article  Google Scholar 

  39. Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009;27(5):805–11.

    Article  Google Scholar 

  40. • Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, et al. Interim positron emission tomography response–adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol. 2016. Additional trial of PET-adapted therapy in advanced Hodgkin lymphoma.

  41. Minuk LA, Monkman K, Chin-Yee IH, Lazo-Langner A, Bhagirath V, Chin-Yee BH, et al. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study. Leuk Lymphoma. 2012;53(1):57–63.

    Article  CAS  Google Scholar 

  42. Anderson RA, Remedios R, Kirkwood AA, Patrick P, Stevens L, Clifton-Hadley L, et al. Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin’s lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. Lancet Oncol. 2018;19(10):1328–37.

    Article  CAS  Google Scholar 

  43. Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol. 2013;31(2):231–9.

    Article  CAS  Google Scholar 

  44. Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2018;390(10114):2790–802.

    Article  Google Scholar 

  45. Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016;34(11):1175–81.

    Article  CAS  Google Scholar 

  46. Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2014;123(11):1658–64.

    Article  CAS  Google Scholar 

  47. Weibull CE, Johansson ALV, Eloranta S, Smedby KE, Bjorkholm M, Lambert PC, et al. Contemporarily treated patients with Hodgkin lymphoma have childbearing potential in line with matched comparators. J Clin Oncol. 2018;36(26):2718–25.

    Article  CAS  Google Scholar 

  48. Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, et al. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol. 2016;34(12):1376–85.

    Article  CAS  Google Scholar 

  49. Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011;29(32):4234–42.

    Article  CAS  Google Scholar 

  50. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–44.

    Article  CAS  Google Scholar 

  51. Ramchandren R, Fanale MA, Rueda A, Armand P, Trněný M, Feldman TA, et al. Nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from the phase 2 Checkmate 205 study. Blood. 2017;130(Suppl 1):651.

    Google Scholar 

  52. Ramchandren R DE, Rueda A, et al. CheckMate 205 cohort D: a phase 2 trial of nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma. Abstract #S114. 23rd Congress of the European Hematology Association; June 15, 2018; Stockholm, Sweden2018.

  53. Eichenauer DA, Plutschow A, Kreissl S, Sokler M, Hellmuth JC, Meissner J, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin’s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol. 2017;18(12):1680–7.

    Article  CAS  Google Scholar 

  54. Stark GL, Wood KM, Jack F, Angus B, Proctor SJ, Taylor PR, et al. Hodgkin’s disease in the elderly: a population-based study. Br J Haematol. 2002;119(2):432–40.

    Article  Google Scholar 

  55. Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park). 2008;22(12):1369–79.

    Google Scholar 

  56. Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119(3):692–5.

    Article  CAS  Google Scholar 

  57. Zallio F, Tamiazzo S, Monagheddu C, Merli F, Ilariucci F, Stelitano C, et al. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). Br J Haematol. 2016;172:879–88.

    Article  Google Scholar 

  58. Sonneveld P, Hop W, Mulder AH, Michiels JJ, Blijham G, van de Lelie J, et al. Full-dose chemotherapy for non-Hodgkin’s lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group. Semin Hematol. 1994;31(2 Suppl 3):9–12.

    CAS  PubMed  Google Scholar 

  59. Nabhan C, Smith SM, Helenowski I, Ramsdale E, Parsons B, Karmali R, et al. Analysis of very elderly (>/=80 years) non-Hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol. 2012;156(2):196–204.

    Article  Google Scholar 

  60. Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett N, Connors JM, et al. Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): analysis from the phase III randomized U.S. intergroup trial E2496. J Clin Oncol. 2011;29(15_suppl):8035.

    Article  Google Scholar 

  61. Boll B, Bredenfeld H, Gorgen H, Halbsguth T, Eich HT, Soekler M, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. 2011;118(24):6292–8.

    Article  Google Scholar 

  62. Ballova V, Ruffer JU, Haverkamp H, Pfistner B, Muller-Hermelink HK, Duhmke E, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005;16(1):124–31.

    Article  CAS  Google Scholar 

  63. Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013;161(1):76–86.

    Article  CAS  Google Scholar 

  64. Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015;385(9976):1418–27.

    Article  CAS  Google Scholar 

  65. Stamatoullas A, Brice P, Bouabdallah R, Mareschal S, Camus V, Rahal I, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015;170(2):179–84.

    Article  CAS  Google Scholar 

  66. Boll B, Goergen H, Behringer K, Brockelmann PJ, Hitz F, Kerkhoff A, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127:2189–92.

    Article  Google Scholar 

  67. Kolstad A, Nome O, Delabie J, Lauritzsen GF, Fossa A, Holte H. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin’s lymphoma. Leuk Lymphoma. 2007;48(3):570–6.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA

    Pamela B. Allen

  2. Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA

    Jane N. Winter

Authors
  1. Pamela B. Allen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jane N. Winter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pamela B. Allen.

Ethics declarations

Conflict of Interest

Pamela B. Allen declares that she has no conflict of interest.

Jane N. Winter has received clinical trial funding (paid to her institution) from Merck and GlaxoSmithKline and has received compensation from Merck, Gilead, Janssen, Adicet Bio, and Bayer for participation on advisory boards.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Lymphomas

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Allen, P.B., Winter, J.N. Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma. Curr Oncol Rep 21, 39 (2019). https://doi.org/10.1007/s11912-019-0788-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-019-0788-0

Keywords

Search

Navigation